Skip to search formSkip to main content

12-hydroxyellipticine

 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

Ellipticines

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2012
2012
Cytochrome b5 increases cytochrome P450 3A4-mediated activation of anticancer drug ellipticine to 13-hydroxyellipticine whose covalent binding to DNA is elevated by sulfotransferases and N,O…
The antineoplastic alkaloid ellipticine is a prodrug, whose pharmacological efficiency is dependent on its cytochrome P450 (P450… Expand
  • figure 1
  • figure 2
  • table 2
  • figure 3
  • figure 4
Is this relevant?
2012
2012
Ellipticine oxidation and DNA adduct formation in human hepatocytes is catalyzed by human cytochromes P450 and enhanced by cytochrome b5.
Ellipticine is an antineoplastic agent considered a pro-drug, the pharmacological and genotoxic effects of which are dependent on… Expand
  • figure 3
  • table 1
  • table 3
  • table 4
Is this relevant?
2009
2009
The mechanism of cytotoxicity and DNA adduct formation by the anticancer drug ellipticine in human neuroblastoma cells.
Ellipticine is an antineoplastic agent, whose mode of action is based mainly on DNA intercalation, inhibition of topoisomerase II… Expand
  • figure 8
  • table 1
  • table 2
  • table 2
  • table 5
Is this relevant?
2009
2009
Cytotoxicity of and DNA adduct formation by ellipticine in human U87MG glioblastoma cancer cells.
OBJECTIVES Ellipticine is a potent antineoplastic agent exhibiting multiple mechanisms of action with promising brain tumor… Expand
Is this relevant?
2007
2007
Mammalian peroxidases activate anticancer drug ellipticine to intermediates forming deoxyguanosine adducts in DNA identical to those found in vivo and generated from 12-hydroxyellipticine and 13…
Ellipticine is a potent antineoplastic agent, whose mode of action is considered to be based mainly on DNA intercalation… Expand
Is this relevant?
2007
2007
DNA adduct formation by the anticancer drug ellipticine in human leukemia HL-60 and CCRF-CEM cells.
Ellipticine induces formation of two DNA adducts in leukemia HL-60 and CCRF-CEM cells, identical with deoxyguanosine adducts… Expand
Is this relevant?
2007
2007
The anticancer drug ellipticine is a potent inducer of rat cytochromes P450 1A1 and 1A2, thereby modulating its own metabolism.
Ellipticine is an antineoplastic agent whose mode of action is based mainly on DNA intercalation, inhibition of topoisomerase II… Expand
  • figure 1
  • table 1
  • figure 3
  • table 2
  • table 3
Is this relevant?
2007
2007
Formation and persistence of DNA adducts of anticancer drug ellipticine in rats.
Ellipticine is an antineoplastic agent, whose mode of antitumor and/or toxic side effects is based on DNA intercalation… Expand
Is this relevant?
2006
2006
Oxidation pattern of the anticancer drug ellipticine by hepatic microsomes - similarity between human and rat systems.
Ellipticine is an antineoplastic agent, whose mode of action is based mainly on DNA intercalation, inhibition of topoisomerase II… Expand
  • figure 1
  • figure 2
  • table 1
  • figure 3
  • figure 4
Is this relevant?
Highly Cited
2004
Highly Cited
2004
The anticancer drug ellipticine forms covalent DNA adducts, mediated by human cytochromes P450, through metabolism to 13-hydroxyellipticine and ellipticine N2-oxide.
Ellipticine is an antineoplastic agent, the mode of action of which is considered to be based on DNA intercalation and inhibition… Expand
  • table 1
  • table 1
  • figure 1
  • figure 4
  • figure 2
Is this relevant?
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE